Abstract
Overview
Introduction
Datamonitor expects the antihypertensives market to reach $37 billion, across
the seven major markets, by 2017. The growth will be driven by the uptake of
Novartis' s Tekturna, as well as increased use of ARBs, and their combinations.
However, the expiries of some key patents, particularly Pfizer' s Norvasc and
Merck' s Cozaar, will restrain market growth.
Scope
- Description of the competitive landscape in antihypertensives across seven
major markets with market definition and overview.
- Definition of the unmet needs in the antihypertensives market.
- Event-driven updated sales forecasts for 2008-17 across the seven major
markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the hypertension
market.
Highlights
The growth rate of the antihypertensive market is declining. The market is
mature and does not present an attractive opportunity for R&D expenditure;
consequently Big Pharma are shying away from the pursuit of novel mechanisms
of action in favour of developing more efficacious combination therapies.
Cozaar' s and Diovan' s patent expiries in the US have the potential to alter
the structure of the antihypertensive market dramatically. Threats of generic
substitution and money-saving healthcare strategies which have plagued other
markets, are now approaching the successful ARB class, and will have an impact
on the whole antihypertensive market.
Novartis is set to strengthen its position in the antihypertensives arena;
Tekturna is expected to achieve moderate sales and together with Exforge form
a potential for market expansion. This however will be set back by the
premature expiry of Pfizer' s Norvasc patent.
Reasons to Purchase
- Quantify the future size of the antihypertensives market and identify
opportunities for new products.
- Learn how recent changes related to product expiries will shape the
antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and
the need for paradigm shift in clinical trial design.
| 
View Cart
